Eli Lilly and Company $LLY Shares Bought by Foguth Wealth Management LLC.

Foguth Wealth Management LLC. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 729.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,440 shares of the company's stock after purchasing an additional 4,784 shares during the quarter. Foguth Wealth Management LLC.'s holdings in Eli Lilly and Company were worth $6,839,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. raised its position in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the last quarter. State Street Corp lifted its stake in Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Bank of America Corp DE bought a new position in Eli Lilly and Company during the 2nd quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after acquiring an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after acquiring an additional 400,538 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 1.1%

LLY stock opened at $1,242.76 on Tuesday. The stock's fifty day simple moving average is $1,180.34 and its two-hundred day simple moving average is $1,111.84. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 1-year low of $793.82 and a 1-year high of $1,292.65. The stock has a market cap of $1.17 trillion, a P/E ratio of 41.70, a P/E/G ratio of 1.67 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business's revenue was up 47.7% compared to the same quarter last year. During the same period last year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts expect that Eli Lilly and Company will post 33.56 EPS for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Omvoh delivered positive pediatric trial results. In the Phase 3 SHINE-2 study, 81% of children with moderately to severely active ulcerative colitis achieved a clinical response after induction, while half of responders reached clinical remission after one year. Lilly plans to submit the data to regulators for a potential pediatric label expansion. Lilly Omvoh pediatric ulcerative colitis trial results
• Positive Sentiment: Foundayo and the broader GLP-1 franchise remain key growth drivers. European regulators recommended approval of Lilly’s oral weight-loss treatment Foundayo, while analysts expect it to continue gaining market share. Strong GLP-1 sales are also expected to support upcoming third-quarter results. European Union regulators recommend Foundayo approval
• Positive Sentiment: Lilly expanded its drug-delivery capabilities. The company signed a collaboration with Metis TechBio valued at up to $1.1 billion, potentially accelerating development of AI-enabled drug-delivery technology. Metis TechBio drug-delivery collaboration
• Neutral Sentiment: Lilly will present updates on several oncology candidates at the ESMO Congress, including treatments targeting ovarian, lung, thyroid and breast cancers. The data could broaden the company’s growth base, although the commercial impact remains dependent on clinical and regulatory outcomes. Lilly oncology pipeline ESMO update
• Negative Sentiment: Competition, valuation and legal exposure are weighing on sentiment. Investors are monitoring a potential GLP-1 price war with Novo Nordisk and Lilly’s dependence on a concentrated weight-loss portfolio. A Pennsylvania lawsuit also alleges that insulin manufacturers and pharmacy-benefit managers inflated insulin prices, adding regulatory and reputational risk. Eli Lilly insulin pricing lawsuit

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares of the company's stock, valued at $14,131,250. This represents a 29.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 over the last three months. 0.14% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a report on Monday, September 28th. Cantor Fitzgerald raised their price target on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an "overweight" rating in a research report on Thursday, October 8th. Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Guggenheim boosted their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a report on Friday, September 18th. Finally, Leerink Partners upped their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a research report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,313.43.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.